Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States

Lars Wilkinson, Barnaby Hunt, Pierre Johansen, Neeraj N Iyer, Tam Dang-Tan, Richard F Pollock, Lars Wilkinson, Barnaby Hunt, Pierre Johansen, Neeraj N Iyer, Tam Dang-Tan, Richard F Pollock

Abstract

Introduction: The National Health and Nutrition Examination Surveys show that many people with type 2 diabetes (T2D) in the USA fail to achieve recommended treatment targets. In the SUSTAIN 7 randomized controlled trial, once-weekly semaglutide (0.5 and 1.0 mg) was superior to comparative doses of dulaglutide (0.75 and 1.5 mg) in reducing glycated hemoglobin (HbA1c) and body weight in people with T2D. The present study estimated the cost per patient achieving HbA1c treatment targets and weight loss responses with once-weekly semaglutide and dulaglutide in the USA.

Methods: Numbers needed to treat and annual cost per patient achieving HbA1c targets (including a triple composite endpoint of HbA1c < 7% without hypoglycemia and no weight gain) or weight loss responses were calculated on the basis of data from SUSTAIN 7 and the annual cost of treatment from a US healthcare payer perspective.

Results: More patients reached HbA1c targets with once-weekly semaglutide than with dulaglutide, and once-weekly semaglutide showed lower costs of control for all modeled endpoints. The cost per patient achieving the triple composite endpoint was USD 11,916 with once-weekly semaglutide 1.0 mg and USD 15,204 with dulaglutide 1.5 mg, representing a 28% larger cost with dulaglutide 1.5 mg. The cost of reaching the target was 68% larger with dulaglutide 0.75 mg versus once-weekly semaglutide 0.5 mg. For each patient achieving an HbA1c < 7%, the cost would be 18% larger with dulaglutide 1.5 mg than with once-weekly semaglutide 1.0 mg.

Conclusions: The cost of bringing one patient to the triple composite endpoint of an HbA1c < 7% without hypoglycemia and no weight gain would be 28% and 68% higher with dulaglutide 1.5 mg relative to once-weekly semaglutide 1.0 mg and dulaglutide 0.75 mg relative to once-weekly semaglutide 0.5 mg, respectively. Once-weekly semaglutide therefore provides better value for money than dulaglutide for the treatment of people with T2D in the USA.

Funding: Novo Nordisk A/S.

Keywords: Costs and cost analysis; Diabetes mellitus, type 2; Glucagon-like peptides; United States.

Figures

Fig. 1
Fig. 1
Design of the SUSTAIN 7 randomized controlled trial
Fig. 2
Fig. 2
Numbers needed to treat to bring one patient to target with once-weekly semaglutide 0.5 and 1.0 mg, and dulaglutide 0.75 and 1.5 mg. HbA1c, glycated hemoglobin
Fig. 3
Fig. 3
Relative cost of control with once-weekly semaglutide 0.5 mg, dulaglutide 0.75 mg, and dulaglutide 1.5 mg versus once-weekly semaglutide 1.0 mg (index = 100). HbA1c, glycated hemoglobin

References

    1. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. . Accessed 20 Nov 2017.
    1. Rowley WR, Bezold C, Arikan Y, Byrne E, Krohe S. Diabetes 2030: insights from yesterday, today, and future trends. Popul Health Manag. 2017;20(1):6–12. doi: 10.1089/pop.2015.0181.
    1. Dall TM, Mann SE, Zhang Y, et al. Distinguishing the economic costs associated with type 1 and type 2 diabetes. Popul Health Manag. 2009;12(2):103–110. doi: 10.1089/pop.2009.12203.
    1. American Diabetes Association Economic costs of diabetes in the US in 2012. Diabetes Care. 2013;36(4):1033–1046. doi: 10.2337/dc12-2625.
    1. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet. 1998;352:837–853. doi: 10.1016/S0140-6736(98)07019-6.
    1. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet. 1998;352:854–865. doi: 10.1016/S0140-6736(98)07037-8.
    1. Ismail-Beigi F, Craven T, Banerji MA, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet. 2010;376:419–430. doi: 10.1016/S0140-6736(10)60576-4.
    1. US Food and Drug Administration. Byetta (Exenatide) Injection Drug Approval Package. . Accessed 20 Nov 2017.
    1. US Food and Drug Administration. Januvia (Sitagliptin Phosphate) Tablets Drug Approval Package. . Accessed 20 Nov 2017.
    1. US Food and Drug Administration. Invokana (canagliflozin) Tablets Drug Approval Package. . Accessed 20 Nov 2017.
    1. American Diabetes Association 6. Glycemic targets. Diabetes Care. 2017;40(Suppl 1):S48–S56. doi: 10.2337/dc17-S009.
    1. American Diabetes Association 7. Obesity management for the treatment of type 2 diabetes. Diabetes Care. 2017;40(Suppl 1):S57–S63. doi: 10.2337/dc17-S010.
    1. American Diabetes Association 8. Pharmacologic approaches to glycemic treatment. Diabetes Care. 2017;40(Suppl 1):S64–S74. doi: 10.2337/dc17-S011.
    1. Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018 doi: 10.1016/S2213-8587(18)30024-X.
    1. Langer J, Hunt B, Valentine WJ. Evaluating the short-term cost-effectiveness of liraglutide versus sitagliptin in patients with type 2 diabetes failing metformin monotherapy in the United States. J Manag Care Pharm. 2013;19(3):237–246.
    1. Hunt B, Mocarski M, Valentine WJ, Langer J. Evaluation of the short-term cost-effectiveness of IDegLira versus continued up-titration of insulin glargine U100 in patients with type 2 diabetes in the USA. Adv Ther. 2017;34(4):954–965. doi: 10.1007/s12325-017-0502-2.
    1. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2017 executive summary. Endocr Pract. 2017;23(2):207–238. doi: 10.4158/EP161682.CS.
    1. Douketis JD, Macie C, Thabane L, Williamson DF. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond) 2005;29(10):1153–1167. doi: 10.1038/sj.ijo.0802982.
    1. TRULICITY Prescribing Information. . Accessed 28 Feb 2018.
    1. Endocrinologic and Metabolic Drug Advisory Committee. Semaglutide subcutaneous once-weekly: treatment to improve glycemic control in adults with type 2 diabetes mellitus. . Accessed 28 Feb 2018.
    1. Lane WS, Weatherall J, Gundgaard J, Pollock RF. Insulin degludec versus insulin glargine U100 for patients with type 1 or type 2 diabetes in the US: a budget impact analysis with rebate tables. J Med Econ. 2017 doi: 10.1080/13696998.2017.1384383.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit